Lv4
430 积分 2021-01-16 加入
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
1个月前
已完结
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
1个月前
已完结
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
1个月前
已关闭
Estimands, Estimators, and Estimates
1个月前
已完结
Estimand
1个月前
已完结
A Likelihood-Based Approach for the Analysis of Longitudinal Clinical Trials with Return-to-Baseline Imputation
1个月前
已完结
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events
1个月前
已完结
Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study
2个月前
已完结
Spironolactone vs Amiloride for Resistant Hypertension
2个月前
已完结
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
